It’s been the same for many years: whenever Nanoform’s price relative to its target price is mentioned in a Kauppalehti article, the share price jumps 15–20%. Today, there was another story about penny stocks where Nanoform’s upside was prominently featured at the top, just as it has been for years. No worries, it will drop back down in the coming days if you want to buy. Let’s wait for actual company-related news—above all, how and on what schedule and cost the marketing authorization for nano-enzalutamide might progress…
5 Likes